Aditxt, Inc. Net Income (Loss) Attributable to Noncontrolling Interest
Aditxt, Inc. (ADTX) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$241.47 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-05-20
- Aditxt, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$241.47K.
- Aditxt, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$529.57K.
- Aditxt, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$162.26K.
- Aditxt, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$138.85K.
- Aditxt, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2025 was -$1.07M.
- Aditxt, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2024 was -$573.57K.
- Aditxt, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2023 was -$9.61K.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$241.47K 10-Q · filed 2026-05-20 | -$771.05K derived: sum of 2 quarters · filed 2026-05-20 | -$933.31K derived: sum of 3 quarters · filed 2026-05-20 | -$1.07M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-12-31 | -$529.57K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$691.84K derived: sum of 2 quarters · filed 2026-03-31 | -$830.69K derived: sum of 3 quarters · filed 2026-03-31 | -$1.07M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$162.26K 10-Q · filed 2025-11-18 | -$301.11K derived: sum of 2 quarters · filed 2025-11-18 | -$543.27K 10-Q · filed 2025-11-18 | -$863.81K derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-06-30 | -$138.85K 10-Q · filed 2025-08-14 | -$381.01K 10-Q · filed 2025-08-14 | -$701.55K derived: sum of 3 quarters · filed 2026-05-20 | -$741.35K derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-03-31 | -$242.16K 10-Q · filed 2026-05-20 | -$562.70K derived: sum of 2 quarters · filed 2026-05-20 | -$602.50K derived: sum of 3 quarters · filed 2026-05-20 | -$676.76K derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | -$320.54K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$360.35K derived: sum of 2 quarters · filed 2026-03-31 | -$434.61K derived: sum of 3 quarters · filed 2026-03-31 | -$573.57K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$39.80K 10-Q · filed 2025-11-18 | -$114.06K derived: sum of 2 quarters · filed 2025-11-18 | -$253.03K 10-Q · filed 2025-11-18 | |
| 2024-06-30 | -$74.26K 10-Q · filed 2025-08-14 | -$213.23K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | -$138.97K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$9.61K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |